Cargando…
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587972/ https://www.ncbi.nlm.nih.gov/pubmed/31354244 http://dx.doi.org/10.2147/DDDT.S137588 |